Survival and the use and costs of hospital services for London AIDS patients treated with AZT

International Journal of STD and AIDS

Volumn 7, Issue 7, 1996, Pages 507-512

  Beck, E J ^a,d   Kupek, E J ^a   Petrou, S ^b   Wadsworth, J ^a   Miller, D L ^a   Pinching, A J ^c   Harris, J R W ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

AIDS patients; AZT; costs; survival; use of services

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COST; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COSTS AND COST ANALYSIS; FEMALE; HOSPITALS, URBAN; HUMANS; LONDON; MALE; ZIDOVUDINE;

EID: 0030449764     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462961918428     Document Type: Article

References (31)

1. Beck EJ, McKevitt C, Kennelly J, Whitaker L, Wadsworth J, Miller DL. Hospital Service Provision for People with AIDS and HIV Infection: a report for the Department of Health 1991. London: Academic Department of Public Health, St Mary's Hospital Medical School, 1991
2. Beck EJ, Whitaker L, Kennelly J, et al. Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre. AIDS 1994;8:379-84
3. Beck EJ, Kennelly J, McKevitt C, et al. Changing use of hospital services and costs at a London AIDS referral centre 1983-1989. AIDS 1994;8:367-77
4. Peters BS, Beck EJ, Coleman DG, et al. Changing disease patterns in patients with AIDS at a referral centre in the United Kingdom: the changing face of AIDS. BMJ 1991;302:203-7
5. CDC Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR, 1987;36(1S): 3S-15S
6. CDSC. AIDS Surveillance and HIV Death Clinical Report Form. London: PHLS Communicable Disease Surveillance Centre, April 1989
7. R User's Guide, Version 6, 4th edn. Vol.2, Cary NC, USA, 1989
8. British Medical Association/Royal Pharmaceutical Society of Great Britain. British National Formulary, Number 20. London: The Pharmaceutical Press, September 1990
9. National Health Service Executive. Inflation Indices, Health Care & Health Services Pay and Prices Index 1992/93. Cherry House, Leeds, 1993
10. McCann K. The work of a specialist AIDS home support team: the views and experiences of patients using the service. J Adv Nurs 1991;16:832-6
11. Wadsworth E, McCann K. Attitudes towards and use of general practitioner services among homosexual men with HIV infection or AIDS. Br J of Gen Pract 1992;42:107-10
12. Petrou S, Dooley M, Whitaker L, et al. Community services for people with HIV infection in London: a prospective study of cost and utilization patterns. Health Trends 1995;27:62-8
13. Allen C, Beecham J. Costing Services: ideals and reality. In: Netten A, Beecham J, eds. Costing Community Care: Theory and Practice. Aldershot: Ashgate Publishing, 1993:25-42
14. Lundgren JD, Philips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;271:1088-92
15. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185-91
16. Dournon E, Matheron S, Rozenbaum W, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988;II:1297-1302
17. Peters BS, Beck EJ, Coleman DG, Moss F, Harris JRW, Pinching AJ. The role of zidovudine in increased survival in AIDS patients. VI International Conference on AIDS, San Francisco, USA, June 1990. Abstract Th.C.696
18. Solomon PJ, Wilson SR, Swanson CE, Cooper DA. Effect of zidovudine on survival of patients with AIDS in Australia. Med J Aust 1990;153:254-7
19. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-16
20. Volberding P, Lagakos S, Koch M, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimetre. N Engl J Med 1990;322:941-9
21. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81
22. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy of HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:145-54
23. Delta Coordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91
24. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. N Engl J Med 1992;326:437-43
25. Santos BR, Beck EJ, Peixoto MF. Survival and medical intervention in southern Brazilian AIDS patients. Int J STD AIDS 1994;5:279-83
26. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81
27. Scitovsky AA, Cline MW, Abrams DI. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. J AIDS 1990;3:904-12
28. Langtry HD, Palmer KJ, Benfield P. Zidovudine: a review of pharmacoeconomic and quality of life considerations for its use in patients with human immunodeficiency virus. Pharmacoeconomics 1993;3(4):309-37
29. Cosler LE, Lambrinos J. Zidovudine's impact on resource use by patients with symptomatic HIV illness: a large sample analysis. Inquiry 1992;29(Fall):345-55
30. Moore RD, Hidalgo J, Bareta JC, Chaisson RE. Zidovudine therapy and health resource utilization in AIDS. J AIDS 1994;7:349-54
31. Crystal S. Problems in estimating cost to death using censored data. IP9.4. AIDS Impact: biopsychosocial aspects of HIV Infection. 2nd International Conference, Brighton UK, 9 July 1994